The Verthermia® team conducted an FDA Phase 1 clinical trial during 2014-2015, resulting in significant findings on the positive impact of the HEATT® (formally VV-PISH) procedure. These findings indicated improved survival rates and the ability to engage in daily living activities. Most of the patients enrolled in the study were in hospice or had advanced unresponsive cancer and completed at least one cycle of HEATT®. HEATT® is a whole-body hyperthermic therapy in which the patient’s blood is heated to the therapeutic level of 42°C for a sustained period of time. Doctors monitor patients’ vitals to ensure that the body systems are functioning properly while exposed to heat. CoreHFC™, a patent-pending device of Verthermia®, ensures that the heated blood is continuously circulated and toxic byproducts removed. All patients in the clinical trial had terminal, stage IV ovarian or peritoneal cancer and failed at least a third-line chemotherapy treatment.